Australia's most trusted
source of pharma news
Saturday, 02 August 2025
Posted 31 July 2025 PM
In what must be one of industry's toughest gigs, Novo Nordisk has named Maziar 'Mike' Doustdar as its new CEO.
He takes the reins from Lars Lars Fruergaard Jørgensen, who steered the company through an extraordinary 250 per cent share price rise and was so popular with staff, they gave him a standing ovation after learning he was being replaced.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.